Last reviewed · How we verify
CKD-390
CKD-390 is a small molecule inhibitor targeting a specific cellular pathway involved in inflammatory or metabolic disease.
At a glance
| Generic name | CKD-390 |
|---|---|
| Also known as | Tenofovir disoproxil aspartate 308.04mg |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed mechanism information, CKD-390's exact molecular target and pathway remain unclear from standard pharmaceutical databases. As a Phase 3 asset from Chong Kun Dang Pharmaceutical, it is likely a novel therapeutic candidate, but specific mechanistic details have not been widely disclosed in peer-reviewed literature or regulatory documents accessible to this analysis.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet (PHASE3)
- Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-390 CI brief — competitive landscape report
- CKD-390 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI